Cargando…
Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is a neoplasm marked by the accumulation of CD1A(+)CD207(+) cells. It is most commonly driven by a somatic, activating mutation in the BRAF serine-threonine kinase (BRAF(V600E)). Multisystem disease with risk-organ involvement requires myelotoxic chemotherapy, mak...
Autores principales: | Eder, Sebastian K., Schwentner, Raphaela, Ben Soussia, Philipp, Abagnale, Giulio, Attarbaschi, Andishe, Minkov, Milen, Halbritter, Florian, Hutter, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945316/ https://www.ncbi.nlm.nih.gov/pubmed/34619771 http://dx.doi.org/10.1182/bloodadvances.2021005442 |
Ejemplares similares
-
Lineage switching of the cellular distribution of BRAF(V600E) in multisystem Langerhans cell histiocytosis
por: Milne, Paul, et al.
Publicado: (2022) -
Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature
por: Heisig, Anne, et al.
Publicado: (2018) -
Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies
por: Hutter, Caroline, et al.
Publicado: (2016) -
Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
por: Donadieu, Jean, et al.
Publicado: (2019) -
A rare case of "switch on and off" multi-system Langerhans cell histiocytosis in an adult patient
por: Karpathiou, Georgia, et al.
Publicado: (2011)